The human EVI5 gene was originally isolated through its involvement with a constitutional chromosome translocation in a patient with stage 4S neuroblastoma. Recently, it has been shown that EVI5 is a centrosomal protein in interphase cells, which relocalizes to the midbody during late phases of mitosis. Disruption of its function leads to incomplete cell division and the formation of multinucleate cells. The EVI5 protein contains a TBC (TRE2/BUB/ CDC16 homology) motif located in the N-terminal region. Proteins containing a TBC domain have been shown in some cases to act as GTPase-activating proteins (GAPs) and function through the interaction with Rab-like small G proteins. Despite the identification of over 50 TBCcontaining proteins, and over 70 Rab-like proteins, only three combinations have been shown to have Rab/GAP activity to date. In this study, using linear ion trap mass spectroscopy, we have demonstrated that EVI5 exists in a protein complex with Rab11. Further, using a specific Rab-binding assay, we have shown that EVI5 preferentially interacts with the guanosine triphosphate-bound form of Rab11, and in a GAP activity assay, we have confirmed that EVI5 functions as a GAP for the Rab11 GTPase.
Proteins with homology to the so-called TBC domain, consisting of an B200-amino-acid motif initially identified in the TRE2/BUB2/CDC16 genes (Richardson and Zon, 1995) , are considered to function as GTPaseactivating proteins (GAPs), partnering with Rab-like small G proteins. Rab GTPases are members of the Ras superfamily of guanosine triphosphate (GTP)-binding proteins that play critical roles in the regulation of important membrane and protein trafficking events in the cell. Many of the Rab proteins are associated with fundamental biological processes such as vesicle fusion, receptor recycling, membrane transport and cytokinesis (Zerial and McBride, 2001 ). There are, however, over 50 human proteins with predicted TBC domains, and over 70 human Rab proteins, of which only two TBC domain-containing proteins have so far been shown to demonstrably have Rab/GAP activity. The human EVI5 protein, which was identified at the breakpoint in a constitutional chromosome translocation in a patient with stage 4S neuroblastoma (Roberts et al., 1998) , contains a TBC domain near its N terminus. EVI5 has been identified in the centrosome in interphase cells (Faitar et al., 2005) and in the midbody during the terminal stages of cytokinesis. Small interfering RNA knockdown of EVI5 results in multinucleate cells because of an inability of daughter cell abscission (Faitar et al., 2006) . Because of the essential role of EVI5 in cytokinesis, as well as its implicated involvement in cancer development, we used a proteomics approach and identified the Rab protein that is activated by the EVI5 TBC domain.
Rab proteins function by cycling between the biologically active GTP-bound form and the guanosine diphosphate (GDP)-bound inactive form. In the active GTP-bound conformation, these proteins can directly interact with specific effectors, thus controlling their function. Guanine nucleotide exchange factors regulate GTPases by promoting the formation of active GTPbound GTPases. In contrast, the GAPs promote inactivation of GTPases by stimulating GTP hydrolysis (Bernards and Settleman, 2005) . The identification of GTPase activator proteins (GAPs) and GTPase exchange factors for each Rab protein, therefore, is critical for understanding the mechanisms that regulate their enzymatic activity and their biochemical function in the cell. To identify proteins that interact with the EVI5 TBC domain, a construct containing the N-terminal 445 amino acids of EVI5 (Faitar et al., 2005) was cloned into the pGEX-5X-1 vector and expressed in Escherichia coli (BL21) as a gluthathione-S-transferase (GST) fusion protein. The bacterially expressed protein was immobilized on glutathione-agarose beads and used in pulldown experiments with total protein extracts from IMR5 neuroblastoma cells. The eluted proteins were then subjected to linear ion trap mass spectroscopy (MS) and, after subtraction of the proteins recovered using a GST-only construct, four putative EVI5 partners of interaction were identified. In addition to the GST bait and the EVI5 protein itself, this analysis identified Rab11 (represented by two different peptides coving B9% of the protein) as a potentially interacting protein (Figure 1 ). To confirm this interaction, the endogenous EVI5 protein was immunoprecipitated (IP) from IMR5 and HeLa cell lysates, using the EVI5 antibody described previously (Faitar et al., 2005) . The presence of Rab11 among the proteins IP with this antibody was analysed using Western blotting with an anti-Rab11 antibody. This experiment identified a protein with the expected 24 kDa molecular weight of Rab11, thus supporting the association between Rab11 and EVI5. In a complementary analysis, pull-down experiments using GST-tagged constructs containing the N-terminal and the C-terminal fragments of EVI5 were performed. Using an anti-Rab11 antibody, an interaction was demonstrated specifically for the N-terminal region of EVI5 (EVI5N) containing the TBC domain. Taken together, both the IP and GST pull-down experiments confirmed that Rab11 exists in a protein complex with EVI5 ( Figure 2 ). Linear ion trap mass spectrometry analysis also identified annexin 6 (represented by five peptides spanning 11% of the protein) in the protein complex with EVI5, which we have independently verified using IP and Western blotting (data not shown), as well as a-and b-tubulin, which we had previously demonstrated are in a complex with EVI5 (Faitar et al., 2005) . These observations demonstrate the precision of the linear ion trap approach. In humans, two highly homologous A and B forms of Rab11 have been identified (Pereira-Leal and Seabra, 2001 ). The MS data identified peptides that were identical in both Rab11A and Rab11B and the localization and functional data support the idea that these >97% homologous proteins probably have the same function (Junutula et al., 2004) , although with the reagents available, we are unable to determine whether EVI5 has a preference for one or the other.
The GST pull-down and IP experiments were performed using cell lysates in vitro, and so it was Linear ion trap MS (Finnigan LTQ) analysis was used to characterize the peptides recovered from GST pull-down experiments using the N-terminal 445 amino acids of EVI5 as the bait. A Thermo Electron nanochromatography system using a split flow rate of 200 nl/min was tuned with Angiotensin II (AGC Target for Full MS of 20 000 and MS n of 10 000) and peptides were identified using the Big 10 MS 2 technique in which the full mass spectrum was acquired from 400 to 2000 m/z, followed by MS/MS of the 10 largest peaks in the full mass spectrum. Dynamic exclusion was enabled with a repeat count of 2 with the exclusion duration set to 60 s to find co-eluting peaks; hence, increasing the dynamic range of the analysis. The tandem mass spectra were acquired with an isolation width of 2.0 m/z and a collision energy of 25%. The resulting chromatograms were searched against a human database sub-setted from the NCBI non-redundant database. DTA files, created using Thermo Electron's Bioworks 3.1 SR1, were searched using Sequest (Eng et al., 1994) . The resulting cross-correlation scores (Xcorr) were then subjected to a rigorous filtering of poor results (peptides where Xcorr was less than 1.8, 2.7 and 3.5 for singly, doubly and triply charged ions, respectively). Proteins were then identified based on their peptides observed. In cases where the sequence coverages are low, the peptides were re-examined to identify the probability that a random match not represented by a statistically significant distribution could have produced a better match to the tandem mass spectrum than the identified peptide actually did (P-score). Those peptides with a probability below 1 in 1000 were further eliminated. The tandem mass spectra for two peptides, DDEYDYLFK and HLTYENVER, corresponding to Rab11 are shown (above and below) and their location within the Rab11 protein sequence is shown in the center. In both cases, the b-and y-product ions (N-terminal and C-terminal, respectively) are labeled and the inset shows the position of the fragmentations observed. possible that these two proteins might not interact in vivo because they are localized to different compartments in the cell. To investigate the relationship between EVI5 and Rab11, we analysed the distribution of the EVI5 and Rab11 proteins in HeLa cells using confocal microscopy (data not shown). As we reported previously (Faitar et al., 2006) , EVI5 localizes to two parallel discs in the center of the midbody, and Rab11 was shown at this stage of the cell cycle to concentrate at the periphery of the cleavage furrow. During interphase, the two proteins colocalized to the pericentriolar region. Previous studies have also shown that Rab11 is located in the pericentriolar endosome recycling compartment (Ullrich et al., 1996) , as well as the trans-Golgi network where it has been suggested to control trafficking between these two compartments (Wilcke et al., 2000) . Our intracellular localization studies, as well as those of others (Horgan et al., 2004; Wilson et al., 2005) , suggests that Rab11 localizes close to the cleavage furrow/ midbody during cytokinesis, suggesting it may be involved in delivering essential endosome-derived proteins to facilitate cell septation. Other centrosomal proteins have also been shown to have Rab/GAP activity. For example, GAPCenA is a GAP for Rab6 (Cuif et al., 1999) , which is also associated with centrosomes. RN-Tre, which is potentially involved in epidermal growth factor receptor endocytosis, has been shown to be a GAP for Rab41 and RabGAP-5 is the GAP for Rab5 (Haas et al., 2005) . Both of these GAPs contain TBC domains. In contrast, the only other Rab/ GAP, Rab3GAP, is associated with Rab3, but does not contain a TBC domain (Fukui et al., 1997) . This protein, like GAPCenA, can also be located in the centrosome, although is predominantly a nuclear protein in interphase cells as is EVI5.
Theoretically, if EVI5 is a GAP that negatively regulates Rab11, it should have a stronger affinity for the active, GTP-bound form of Rab11 rather than the inactive GDP-bound form. To determine the affinity of EVI5 for Rab11, we incubated serum-starved IMR5 whole-cell lysates with either GTP-gS, a non-hydrolysable form of GTP, or GDP-bS, a non-phosphorylatable form of GDP. Treatment with these nucleotides shifts the equilibrium toward either active Rab11, in the case of GTP-gS, or inactive Rab11, in the case of GDPbS. After incubation, the GST pull-down assays were performed by incubating the N-terminal EVI5-GST fusion protein with either the GTP-gS-treated lysate or the GDP-bS-treated lysate. The proteins eluted were analysed by Western blotting with an anti-Rab11
Figure 3 EVI5-TBC domain has stronger affinity for the active, GTP-bound form of Rab11. Glutathione agarose columns preloaded with GST-EVI5N were incubated with IMR5 total protein lysates treated with GTPgS and GDPbS, respectively. Western blot analysis (a) was used to detect the amount of Rab11 protein pulled down by the GST-EVI5N fusion protein in the different cell lysates compared with the GST loading control (below). The signal intensity in this image (a) is saturated because of prolonged exposure of the film. In (b), the counts measured by phosphorimaging (performed in duplicate) are shown graphically. An B14-fold increase in EVI5 binding affinity was seen when Rab 11 was in the GTP-bound form (the cells were treated with GTPgS), compared with the GDP-bound form (when the cells were incubated with GDPbS). As a control (c), untreated IMR5 lysates were used. Figure 4 GAP assay for the EVI5 TBC domain. EVI5 cDNA fragments were polymerase chain reaction amplified and cloned into pGEX, and expressed in Escherichia coli BL-21 cells. Similarly, Rab11 and Rab4 were cloned into a pRSET vector, and expressed as His 6 -tagged proteins. Glutathione-agarose beads were used to immobilize the GST-EVI5 fusion protein and Ni-NTA agarose beads were used to immobilize the Rab11-and Rab4-(His) 6 fusion proteins. Beads were washed three times to remove residual bacterial proteins. The GTPase reaction (a) was performed in 400 ml of GAP assay reaction buffer (20 mM Tris, pH 8, 10 mM MgCl 2 and 1 mM dithiothreitol) treated with 2.8 mCi [a- antibody. Increased amounts of Rab11 were recovered from the GTP-gS-treated protein lysate compared with the GDP-bS-treated lysate (Figure 3 ). Western blot analysis using an anti-GST antibody indicated equivalent amounts of EVI5 were bound to the beads before incubation with the whole-cell lysates (Figure 3) . Phosphorimaging analysis demonstrated that there was a 14-fold increase in recovered Rab11 when protein lysates were treated with GTP-gS, compared with the amount of Rab11 from lysates treated with GDP-bS. These results demonstrate that the TBC-containing N-terminal part of EVI5 has a greater affinity for the GTP-bound active form of Rab11 compared with the inactive GDPbound form of Rab11.
To determine whether the preferential binding of the EVI5 TBC domain to GTP-bound Rab11 affects its enzyme activity, we used a modified form of the GAP assay described by Liu and Li (1998) , which assesses the ability of protein complexes to hydrolyse GTP to GDP in the presence of [a- (Figure 4) . In this assay, the conversion of GTP to GDP was monitored using phosphorimaging, where the rate of hydrolysis is related to the relative input of the TBC-GAP function from EVI5. As shown in Figure 4 , the hydrolysis of GTP to GDP was proportional to the relative concentration of the EVI5-GAP in the reaction. As a negative control, to demonstrate specific GAP activity of EVI5 toward Rab11, Rab4, which is also involved in endosome recycling (Bottger et al., 1996; Daro et al., 1996; Ward et al., 2005) , was similarly cloned and expressed as a (His) 6 fusion protein and used in the GAP assay with EVI5N. The results shown in Figure 4 demonstrate that GTP hydrolysis occurs efficiently when EVI5N is included with Rab11 in the in vitro GTPase reaction. In contrast, EVI5N did not affect the GTPase activity of Rab4. When EVI5C was substituted in either of these reactions, there was no significant increase in the rate of GTP hydrolysis. In these experiments, a fourfold increase in the concentration of the potential GAP construct (EVI5N) resulted in an approximate fourfold increase in the rate of GTP hydrolysis. These analyses demonstrate that the EVI5 TBC domain specifically functions as a GAP for the Rab11 GTPase. The fact that only Rab11 was identified in the MS analysis further supports a specific functional association with Rab11.
In this report, we describe the interaction between EVI5 and Rab11 and demonstrate that the TBC domain in EVI5 functions as a GAP for this small GTPase. GAPs enhance the inherently slow GTPase activity of G proteins, causing their inactivation and thus modulating the cellular pathways controlled by the respective G proteins. This functional interaction appears to be important in cytokinesis and potentially in centrosome function. Given the importance of vesicle traffic to the cleavage furrow during cell abscission, it is tempting to speculate that the EVI5-Rab11 interaction may be important in the protein transport events that facilitate this process.
